Evidence map›Paper›PMID 39976811›Full record

ArticleArchives of dermatological research2025

IgA vasculitis induced by tumor necrosis factor-α antagonists: clinical features, diagnosis and management.

Lu Yan, Jie Shen, Lin Liu, Minghua Yang, Shengfeng Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lu YanDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Jie ShenDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Lin LiuDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Minghua YangDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China. yangminghua@csu.edu.cn.
Shengfeng WangDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China. sunfeelwang@csu.edu.cn.

Funding

Health Research Project of Hunan Provincial Health Commission W20242008Health Research Project of Hunan Provincial Health Commission W20243126the National Natural Science Foundation of China 82102280the National Natural Science Foundation of China 82202398the National Natural Science Foundation of China 82270185the Science and Technology Innovation Program of Hunan Province 2022RC3077
6 · The paper itself

Abstract

introductionAnti-TNF therapies are commonly employed in the treatment of autoimmune disorders, yet they are associated with a rare side effect known as IgA vasculitis (IgAV), whose clinical presentation remains poorly understood. This study aims to clarify the features of IgAV linked to anti-TNF treatments to aid in prompt recognition and management.

methodsCase reports on TNF-α-antagonist-associated IgAV dated up to February 29, 2024, were retrieved for retrospective analysis.

resultsA total of 35 cases from 30 publications were identified. The average age of patients was 36 years (range 11 to 69), with 31.4% being pediatric cases. The primary conditions treated were Crohn's disease (45.7%) and ulcerative colitis (22.9%). Infliximab (42.9%) and adalimumab (37.1%) were the most frequently used agents. The onset of IgAV after initiating anti-TNF therapy occurred at a median of 10 months (range 1 day to 11 years). Clinical symptoms predominantly involved the skin (97.1%), kidneys (68.6%), joints (57.1%), and gastrointestinal tract (40.0%). Renal failure developed in 11.4% of patients. Histopathology revealed leukocytoclastic vasculitis in the skin and mainly proliferative nephritis in renal biopsies, with significant IgA deposition observed. Most patients (80.0%) ceased anti-TNF treatment, and the majority received corticosteroids (96.2%) and dapsone (15.4%) as part of their treatment. Remission was achieved in 34 patients, while one patient worsened. Among the 14 patients who restarted anti-TNF therapy, 9 experienced a recurrence of IgAV.

conclusionIgAV associated with anti-TNF therapy may emerge months into treatment and can lead to severe renal complications necessitating ongoing surveillance. Halting anti-TNF therapy is imperative, but the decision to resume treatment must be weighed carefully against the risk of primary disease exacerbation and IgAV recurrence.

Indexed as

IgA VasculitisImmunoglobulin ATumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsVasculitisAdalimumabAdolescentAdultAgedChildColitis, UlcerativeCrohn DiseaseFemaleHumansInfliximabMaleAdalimumabImmunoglobulin AInfliximabTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAdverse eventsAutoimmune diseasesIgA vasculitisIgA with nephropathyTNF-α antagonist

Identifiers

PMID39976811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.